Fertility drugs and ovarian cancer

Epidemiologic Reviews

Volumn 20, Issue 2, 1998, Pages 237-257

  Glud, Eva ^a   Kjær, Susanne Krüger ^a   Troisi, Rebecca ^b   Brinton, Louise A ^b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE; FOLLITROPIN; GONADORELIN AGONIST; LUTEINIZING HORMONE;

CANCER RISK; FEMALE INFERTILITY; OVARY CANCER; OVULATION INDUCTION; PRIORITY JOURNAL; REVIEW;

EID: 0032412039     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017983     Document Type: Review

References (157)

1. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-203.
2. Bamford PN, Steele SJ. Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy: case report. Br J Obstet Gynaecol 1982;89:962-4.
3. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary: a possible association. Acta Obstet Gynecol Scand 1982;61:261-3.
4. Ben-Hur H, Dgani R, Lancet M, et al. Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 1986;65:813-14.
5. Carter ME, Joyce DN. Ovarian carcinoma in a patient hyperstimulated by gonadotrophin therapy for in vitro fertilization: a case report. J In Vitro Fert Embryo Transf 1987;4:126-8.
6. Kulkarni R, McGarry JM. Follicular stimulation and ovarian cancer. (Letter). BMJ 1989;299:740.
7. Lappöhn RE, Burger HG, Bouma J, et al. Inhibin as a marker for granulosa-cell tumors. N Engl J Med 1989;321:790-3.
8. Dietl J. Ovulation and ovarian cancer. (Letter). Lancet 1991; 338:445.
9. Goldberg GL, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - is there a link? Am J Obstet Gynecol 1992;166:853-4.
10. Nijman HW, Burger CW, Baak JP, et al. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur J Cancer 1992;28A:1971-3.
11. Lopes P, Mensier A. Ovarian cancer and assisted reproductive technology. Eur J Obstet Gynecol Reprod Biol 1993;51: 171-3.
12. Willemsen W, Kruitwagen R, Bastiaans B, et al. Ovarian stimulation and granulosa-cell tumour. Lancet 1993;341: 986-8.
13. Balasch J, Barri PN. Follicular stimulation and ovarian cancer? Hum Reprod 1993;8:990-6.
14. Karlan BY, Marrs R, Lagasse LD. Advanced-stage ovarian carcinoma presenting during infertility evaluation. Am J Obstet Gynecol 1994;171:1377-8.
15. Komatsu T, Konishi I, Mandai M, et al. Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation-induction therapy: immunohistochemical expression of LH/hCG receptors. Gynecol Oncol 1995;56:470-4.
16. Grimbizis G, Tarlatzis BC, Bontis J, et al. Two cases of ovarian tumours in women who had undergone multiple ovarian stimulation attempts. Hum Reprod 1995;10:520-3.
17. Unkila-Kallio L, Leminen A, Tiitinen A, et al. Malignant tumors of the ovary or the breast in association with infertility: a report of thirteen cases. Acta Obstet Gynecol Scand 1997;76:177-81.
18. Jourdain O, Avril A, Mauriac L, et al. Breast cancer and in vitro fertilization: about 32 cases. Eur J Obstet Gynecol Reprod Biol 1996;67:47-52.
19. Brzezinski A, Peretz T, Mor-Yosef S, et al. Ovarian stimulation and breast cancer: is there a link? Gynecol Oncol 1994;52:292-95.
20. Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987;125:780-90.
21. Brinton LA, Melton LJ III, Malkasian GD Jr, et al. Cancer risk after evaluation for infertility. Am J Epidemiol 1989; 129:712-22.
22. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995-1000.
23. Rossing MA, Daling JR, Weiss N, et al. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996;60:3-7.
24. Rossing MA, Daling JR, Weiss NS, et al. In situ and invasive cervical carcinoma in a cohort of infertile women. Fertil Steril 1996;65:19-22.
25. Cowan LD, Gordis L, Tonascia JA, et al. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981;114:209-17.
26. Coulam C, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983; 61:403-7.
27. Westhoff C. Infertility and breast cancer risk. (Editorial). Gynecol Oncol 1996;60:1-2.
28. Spirtas R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril 1993; 59:291-3.
29. Rossing MA, Daling JR, Weiss NS. Risk of ovarian cancer after treatment for infertility. (Letter). N Engl J Med 1995; 332:1302.
30. Shoham Z. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 1994;62:433-48.
31. Lunenfeld B, Insler V. Induction of ovulation: historical aspects. Baillieres Clin Obstet Gynaecol 1990;4:473-89.
32. Wysowski DK. Use of fertility drugs in the United States, 1973 through 1991. Fertil Steril 1993;60:1096-8.
33. Shapiro S. Risk of ovarian cancer after treatment for infertility. (Letter). N Engl J Med 1995;332:1301.
34. Blacker CM. Ovulation stimulation and induction. Endocrinol Metab Clin North Am 1992;21:57-84.
35. Derman SG, Adashi EY. Adverse effects of fertility drugs. Drug Saf 1994;11:408-21.
36. Forman RG, Demouzon J, Feinstein MC, et al. Studies on the influence of gonadotrophin levels in the early follicular phase on the ovarian response to stimulation. Hum Reprod 1991; 6:113-17.
37. Clark JH, Markaverich BM. The agonistic-antagonistic properties of clomiphene: a review. Pharmacol Ther 1981;15: 467-519.
38. Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action - hypothesis revisited. Fertil Steril 1984;42:331-44.
39. Kerin JF, Liu JH, Phillipou G, et al. Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab 1985;61:265-8.
40. Roy S. Early developmental studies with clomiphene citrate: their subsequent validation and extension. Indian J Exp Biol 1992;30:931-46.
41. March CM. Ovulation induction. J Reprod Med 1993;38: 335-46.
42. Quigley MM, Berkowitz AS, Gilbert SA, et al. Clomiphene citrate in an in vitro fertilization program: hormonal comparisons between 50- and 150-mg daily dosages. Fertil Steril 1984;41:809-15.
43. Randall JM, Templeton A. The effects of clomiphene citrate upon ovulation and endocrinology when administered to patients with unexplained infertility. Hum Reprod 1991;6: 659-64.
44. Glasier AF. Clomiphene citrate. Baillieres Clin Obstet Gynaecol 1990;4:491-501.
45. MacDougall MJ, Tam SL, Hall V, et al. Comparison of natural with clomiphene citrate-stimulated cycles in in vitro fertilization: a prospective, randomized trial. Fertil Steril 1994;61:1052-7.
46. Fluker MR, Urman B, Mackinnon M, et al. Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders. Obstet Gynecol 1994;83:189-96.
47. Nilsson L, Hamberger L. Human gonadotrophins. Ballieres Clin Obstet Gynaecol 1990;4:503-18.
48. Fishel S, Jackson P. Follicular stimulation for high tech pregnancies: are we playing it safe? BMJ 1989;299:309-11.
49. Insler V. Gonadotropin therapy: new trends and insights. Int J Fertil 1988;33:85-6, 89-97.
50. Shoham Z, Homburg R, Jacobs HS. Induction of ovulation with pulsatile GnRH. Baillieres Clin Obstet Gynaecol 1990; 4:589-608.
51. Hedon B, Bringer J, Arnal F, et al. The use of GnRH agonists with hMG for induction or stimulation of ovulation. Baillieres Clin Obstet Gynaecol 1990;4:575-87.
52. Pellicer A, Tarin JJ, Miró F, et al. The use of gonadotrophin releasing-hormone analogues (GnRHa) in in-vitro fertilization: some clinical and experimental investigations of a direct effect on the human ovary. Hum Reprod 1992;7:39-47.
53. International Agency for Research on Cancer. Clomiphene citrate (group 3). A. Evidence for carcinogenicity to humans. In: IARC monographs on the evaluation of carcinogenic risks to humans, supplement 7. Lyon, France: International Agency for Research on Cancer, 1987:172-73.
54. Cunha GR, Taguchi O, Namikawa R, et al. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol 1987;18:1132-43.
55. Ohnishi T, Ohashi Y, Amano I, et al. An ovulation inducing agent containing clomiphene citrate causes DNA-strand breaks without SOS responses in Escherichia coli. Mutat Res 1986;165:57-61.
56. Brinton LA, Hoover RN. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia, PA: Lippincott, 1992:3-26.
57. Braga C, Negri E, La Vecchia C, et al. Fertility treatment and risk of breast cancer. Hum Reprod 1996;11:300-3.
58. Rossing MA, Daling JR, Weiss NS, et al. Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res 1995;5:123-7.
59. Healy DL, Trounson AO, Andersen AN. Female infertility: causes and treatment. Lancet 1994;343:1539-44.
60. Templeton A, Fraser C, Thompson B. Infertility - epidemiology and referral practice. Hum Reprod 1991;6: 1391-4.
61. Schmidt L, Münster K. Infertility, involuntary infecundity, and the seeking of medical advice in industrialized countries 1970-1992: a review of concepts, measurements and results. Hum Reprod 1995;10:1407-18.
62. Gunnell DJ, Ewings P. Infertility prevalence, needs assessment and purchasing. J Public Health Med 1994;16:29-35.
63. Mosher WD, Pratt WF. The demography of infertility in the United States. In: Asch RH, Stubb JW, eds. Annual progress in reproductive medicine. Park Ridge, NJ: Parthenon Publishing Group, 1993:37-43.
64. Wilcox LS, Mosher WD. Use of infertility services in the United States. Obstet Gynecol 1993;82:122-7.
65. US Congress, Office of Technology Assessment. Infertility: medical and social choices. Washington, DC: US GPO, 1988. (Publication no. OTA-BA-358).
66. Mosgaard B, Lidegaard Ø, Andersen AN. Use of fertility drugs in Denmark 1973-1993: an analysis based on sale statistics. Acta Obstet Gynecol Scand 1995;74:614-18.
67. Gore H. Histopathology of ovarian cancer. Semin Surg Oncol 1994;10:255-60.
68. Krigman H, Bentley R, Robboy SJ. Pathology of epithelial ovarian tumors. Clin Obstet Gynecol 1994;37:475-91.
69. Evans AT III, Gaffey T, Malkasian GD Jr, et al. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980;55:231-8.
70. Merino MJ, Jaffe G. Age contrast in ovarian pathology. Cancer 1993;71:537-44.
71. Trimble CL, Trimble EL. Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1994; 55(suppl):S52-61.
72. Coleman MP, Esteve J, Damiecki P, et al. Trends in cancer incidence and mortality. Lyon, France: International Agency for Research on Cancer, 1993:1-806. (IARC scientific publication no. 121).
73. Parazzini F, Restelli C, La Vecchia C, et al. Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol 1991:20:871-7.
74. Yancik R. Ovarian cancer: age contrast in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993; 71:517-23.
75. Mant JW, Vessey MP. Ovarian and endometrial cancers. Cancer Surv 1994;19-20:287-307.
76. Kaern J, Tropé CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982: a review of clinicopathologic features and treatment modalities. Cancer 1993; 71:1810-20.
77. Ewertz M, Kjaer SK. Ovarian cancer incidence and mortality in Denmark, 1943-1982. Int J Cancer 1988;42:690-6.
78. Kjaer SK, Storm HH. Survival of Danish cancer patients 1943-1987: female genital organs. APMIS Suppl 1993;33: 107-21.
79. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993;12:120-7.
80. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139:654-61.
81. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987;316:650-5.
82. Gwinn ML, Lee NC, Rhodes PH, et al. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990;43:559-68.
83. Negri E, Franceschi S, Tzonou A, et al. Pooled analysis of 3 European case-control studies. I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991;49:50-6.
84. Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case-control studies of ovarian cancer. II. Age at menarche and at menopause. Int J Cancer 1991;49:57-60.
85. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 1995;62:78-84.
86. Kreiger N, Sloan M, Cotterchio M, et al. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol 1997; 26:710-15.
87. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer: a prospective study. JAMA 1993;270:2813-18.
88. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility and the risk of epithelial ovarian cancer. Am J Epidemiol 1994;140:585-97.
89. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344: 1250-4.
90. Bernstein L, Ross RK, Henderson BE. Relationship of hormone use to cancer risk. J Natl Cancer Inst Monogr 1992; 12:137-47.
91. Gallion HH, Smith SA. Hereditary ovarian carcinoma. Semin Surg Oncol 1994;10:249-54.
92. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989;60:592-8.
93. McGowan L, Parent L, Lednar W, et al. The woman at risk for developing ovarian cancer. Gynecol Oncol 1979;7:325-44.
94. Joly DJ, Lilienfeld AM, Diamond EL, et al. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol 1974;99:190-209.
95. Hange P, Schiffman MH, Hoover R, et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989;161:10-16.
96. Whittemore AS, Wu ML, Paffenbarger PS Jr, et al. Epithelial ovarian cancer and ability to conceive. Cancer Res 1989;49: 4047-52.
97. Chen Y, Wu PC, Lang JH, et al. Risk factors for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 1992;21: 23-9.
98. Nasca PC, Greenwald P, Chorost S, et al. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol 1984;119:705-13.
99. Mosgaard B, Lidegaard Ø, Kjaer SK, et al. Infertility, fertility drugs and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005-12.
100. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-6.
101. Harlow BL, Weiss NS, Roth GJ, et al. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988;48: 5849-52.
102. Harris R, Whittemore AS, Itnyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992;136: 1204-11.
103. Lais CW, Williams TJ, Gaffey TA. Prevalence of ovarian cancer found at the time of infertility microsurgery. Fertil Steril 1988;49:551-3.
104. Franceschi S, La Vecchia C, Negri E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994;9:1673-5.
105. Shushan A, Paltiel O, Iscovich J, et al. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65:13-18.
106. Horn-Ross PL, Whittemore AS, Harris R, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. VI. Nonepithelial cancers among adults. Collaborative Ovarian Cancer Group. Epidemiology 1992;3:490-5.
107. Harlow BL, Weiss NS, Lofton S. Epidemiology of borderline ovarian tumors. J Natl Cancer Inst 1987;78:71-4.
108. Del Priore G, Robischon K, Phipps WR. Risk of ovarian cancer after treatment for infertility. (Letter). N Engl J Med 1995;332:1300.
109. Rossing MA, Weiss NS. Fertility drugs and breast and ovarian cancer. (Letter). Lancet 1995;346:1627-8.
110. Whittemore AS, Harris R, Itnyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Am J Epidemiol 1992; 136:1175-83.
111. Cramer DW, Hutchison GB, Welch WR, et al. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983;71:711-16.
112. Cohen J, Forman R, Harlap S, et al. IFFS expert group report on the Whittemore study related to the risk of ovarian cancer associated with the use of infertility agents. Hum Reprod 1993;8:996-9.
113. Caro JJ, Johannes CB, Hartz SC, et al. Re: "Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women." (Letter). Am J Epidemiol 1993;137:928.
114. International Federation of Fertility Societies. Fertility drugs and ovarian cancer. Fertil Steril 1993;60:406-8.
115. La Vecchia C, Negri E, Parazzini F, et al. Fertility drugs and breast and ovarian cancer. (Letter). Lancet 1995;346:1628.
116. Preston-Martin S, Pike MC, Ross RK, et al. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. In: Butterworth BE, Slaga TJ, Farland W, et al., eds. Chemically induced cell proliferation: implications for risk assessment. Proceedings of the Chemically Induced Cell Proliferation Conference, Austin, Texas, November 29-December 2, 1989. New York, NY: Wiley-Liss, 1991:21-34.
117. Watanabe S, Kobayashi Y. Exogenous hormones and human cancer. Jpn J Clin Oncol 1993;23:1-13.
118. Bast RC Jr, Boyer CM, Jacobs I, et al. Cell growth regulation in epithelial ovarian cancer. Cancer 1993;71:1597-601.
119. Kodama M, Kodama T. An essay on the nature of hormonal codes involved in the genesis of human neoplasias (review). Anticancer Res 1994;14:2653-65.
120. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;2:163.
121. Whittemore AS, Harris R, Itnyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Am J Epidemiol 1992;136:1212-20.
122. Radisavljevic SV. The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol 1977;49:424-9.
123. Dietl J, Marzusch K. Ovarian surface epithelium and human ovarian cancer. Gynecol Obstet Invest 1993;35:129-35.
124. Godwin AK, Perez RP, Johnson SW, et al. Growth regulation of ovarian cancer. Hematol Oncol Clin North Am 1992;6:829-41.
125. Westhoff C, Murphy P, Heller D, et al. Is ovarian cancer associated with an increased frequency of germinal inclusion cysts? Am J Epidemiol 1993;138:90-3.
126. Lowry S, Russell H, Hickey I, et al. Incessant ovulation and ovarian cancer. Lancet 1991;337:1544-5.
127. Russell SE, Hickey GI, Lowry WS, et al. Allele loss from chromosome 17 in ovarian cancer. Oncogene 1990;5:1581-3.
128. Børresen AL. Oncogenesis in ovarian cancer. Acta Obstet Gynecol Scand Suppl 1992;155:25-30.
129. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993;71:566-72.
130. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
131. Boente MP, Hurteau J, Rodriquez GR, et al. The biology of ovarian cancer. Curr Opin Oncol 1993;5:900-7.
132. Stadel BV. The etiology and prevention of ovarian cancer. (Letter). Am J Obstet Gynecol 1975;123:772-4.
133. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
134. Biskind MS, Biskind GS. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 1944;55:176-9.
135. Blaakaer J, Baeksted M, Micic S, et al. Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 1995;53: 775-9.
136. Qayum A, Gullick WJ, Waxman J. Gonadotrophin-releasing hormone: physiological significance and relevance to cancer. Prog Growth Factor Res 1991;3:115-30.
137. Graves PE, Surwit EA, Davis JR, et al. Adenylate cyclase in human ovarian cancers: sensitivity to gonadotropins and non-hormonal activators. Am J Obstet Gynecol 1985;153:877-82.
138. Kammerman S, Demopoulos RI, Raphael C, et al. Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 1981;12:886-90.
139. Peng C, Fan NC, Ligier M, et al. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 1994;135:1740-6.
140. Nakano R, Kitayama S, Yamoto M, et al. Localization of gonadotropin binding sites in human ovarian neoplasms. Am J Obstet Gynecol 1989;161:905-10.
141. Davy M, Torjesen PA, Aakavaag A. Demonstration of an FSH receptor in a functioning granulosa cell tumour: the effect of gonadotrophin treatment on its viability following transplantation to nude mice. Acta Endocrinol (Copenh) 1977;85:615-23.
142. Rajaniemi H, Kauppila A, Rönnberg L, et al. LH(hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand Suppl 1981;101:83-6.
143. Hahlin M, Crona N, Knutsson F, et al. Human granulosa cell tumor: stimulation of steroidogenesis by gonadotropins in vitro. Gynecol Oncol 1991;40:201-6.
144. Simon WE, Albrecht M, Hansel M, et al. Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 1983; 70:839-45.
145. +. Contraception 1976;14:171-81.
146. Rodriguez C, Calle EE, Coates JR, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:828-35.
147. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926-30.
148. Blaakaer J, Djursing H, Hørding U, et al. The pituitary-gonadal axis in women with benign or malignant ovarian tumors. Acta Endocrinol (Copenh) 1992;127:127-30.
149. Blaakaer J, Bennett P, Micic S, et al. The post-operative gonadotrophin level in post-menopausal women with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1993; 52:111-16.
150. Blaakaer J, Micic S, Morris ID, et al. Immunoreactive inhibin-production in post-menopausal women with malignant epithelial ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1993;52:105-10.
151. Healy DL, Burger HG, Mamers P, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993;329:1539-42.
152. Harlow BL, Hartge PA. A review of perineal talc exposure and risk of ovarian cancer. Regul Toxicol Pharmacol 1995; 21:254-60.
153. Cramer DW, Harlow BL, Willett WC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989;2:66-71.
154. Coughlin SS, Benichou J, Weed DL. Attributable risk estimation in case-control studies. Epidemiol Rev 1994;16:51-64.
155. Rosen B, Irvine J, Ritvo P, et al. The feasibility of assessing women's perceptions of the risks and benefits of fertility drug therapy in relation to ovarian cancer risk. Fertil Steril 1997;68:90-4.
156. Weiss NS. Measuring the separate effects of low parity and its antecedents on the incidence of ovarian cancer. Am J Epidemiol 1988;128:451-5.
157. Burger CW, Klip WA, Schippers MC, et al. Ovarian stimulation and gynecologic abnormalities: a Dutch study for potential diseases in the female after in vitro fertilization (IVF). (Abstract). J Assist Repro Genet 1997;14(suppl): 160S.